Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Treatment-resistant depression
Humanistic burden and health-related quality of life
8 evidence topics · 8 sources
Quality of life, functioning, and work productivity in TRD versus non-TRD MDD: Sequenced Treatment Alternatives to Relieve Depression trial secondary analysis
“A total of 2467 (TRD: 377; non-TRD: 2090) patients were studied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, TRD patients had lower health-related quality of life (HRQOL) scores on mental (30 vs 45.7) and physical components (47.7 vs 48.9) of the SF12, and lower Q-LES-Q scores (43.6 vs 63.7), greater functional and work impairments and productivity loss vs non-TRD patients (all p < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L utility and work productivity in TRD versus non-TRD MDD: United Kingdom non-interventional study
“148 patients with clinician-verified symptomatic (non-treatment-resistant) MDD (Patients-MDD; n = 61) or TRD (Patients-TRD; n = 87) were recruited from ten clinical sites.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, HRQoL was significantly poorer for Patients-TRD compared with Patients-MDD, both in the overall cohort (median EQ-5D-5 L utility 0.606/0.721, respectively [p = 0.021]; WHOQOL-BREF overall score 55.2/58.8 [p = 0.024]) and in patients with a PHQ-9 score ≥15 (median EQ-5D-5 L utility 0.415/0.705, respectively [p<0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although a numerically lower proportion of Patients-TRD were employed (45% vs 57% of Patients-MDD; p = 0.204), employed Patients-MDD reported significantly higher absenteeism and work productivity loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L, SF-12v2, and work and activity impairment versus non-TRD depression and the general population: five European countries
“A total 52,060 survey respondents were examined, of which 2686 and 622 were considered to have non-treatment resistant and treatment-resistant depression, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to the general population, nTRD and TRD respondents reported significant decrements in health-related quality of life, including lower adjusted mental (− 12.1 vs. -18.1) and physical (− 2.5 vs. -5.4) component scores of the SF-12v2 and increased adjusted relative risk for work (2.2 vs. 2.7) and activity (1.9 vs. 2.5) impairment (all p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for demographics and health characteristics, TRD and nTRD groups had poorer health status as assessed by the EQ-5D-5 L (− 0.329 and − 0.173, respectively, both p < 0.001) and EQ-VAS (− 27.440 and − 16.724, respectively, both p < 0.001) compared to the general population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L, employment, and work productivity at treatment initiation: European real-world TRD cohort
“Overall, 411 eligible patients were enrolled across seven European countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proportion reporting problems on each EQ-5D-5L dimension at baseline: esketamine phase 3 trial population
“The full analysis set included 223 patients (ESK + AD: 114; AD + PBO: 109; mean [SD] age: 45.7 [11.89]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| EQ-5D-5L dimension | Esketamine plus antidepressant group at baseline, % | Antidepressant plus placebo group at baseline, % |
|---|---|---|
| Mobility | “28.1”View highlighted excerpt for this quote | “34.9”View highlighted excerpt for this quote |
| Self-care | “53.5”View highlighted excerpt for this quote | “53.2”View highlighted excerpt for this quote |
| Usual activities | “94.8”View highlighted excerpt for this quote | “92.7”View highlighted excerpt for this quote |
| Pain/Discomfort | “68.5”View highlighted excerpt for this quote | “74.3”View highlighted excerpt for this quote |
| Anxiety/Depression | “98.3”View highlighted excerpt for this quote | “99.9”View highlighted excerpt for this quote |
Quality-of-life decrement versus remission or response: systematic review of United States data, 1996 to 2013
“Sixty-two articles were included (N=59,462 patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Quality-of-life scores (scale of 0-1, with 0 indicating death and 1 indicating perfect health) for patients with treatment-resistant depression were .41±.8 and .26±.8 points lower, respectively, than for patients who experienced remission or response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life across increasing levels of non-response: systematic review
“Likewise, the 19 studies studying HRQoL burden found that increasing levels of TRD/non-response correlated with reduced patient HRQoL and health status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A consistent trend was observed such that medical costs increased and patient HRQoL and health status decreased by increasing level of TRD/non-response within an MDD episode.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote